TY - JOUR
T1 - Lipoprotein(a) and Cardiovascular Disease in Chinese Population
T2 - A Beijing Heart Society Expert Scientific Statement
AU - Beijing Heart Society and Expert Committee
AU - Li, Jian Jun
AU - Ma, Chang Sheng
AU - Zhao, Dong
AU - Yan, Xiao Wei
AU - Li, Jianjun
AU - Yan, Xiaowei
AU - Ye, Ping
AU - Chen, Hong
AU - Li, Yong
AU - Yuan, Zuyi
AU - Zhang, Ruiyan
AU - Zhao, Shuiping
AU - Lu, Guoping
AU - Liang, Chun
AU - Dong, Yugang
AU - Chen, Zhenyue
AU - Peng, Daoquan
AU - Tang, Yida
AU - Wang, Fang
AU - Zhou, Zhou
AU - Sun, Yihong
AU - Liu, Jing
AU - Guo, Yuanlin
AU - Yuan, Hui
AU - Wu, Naqiong
AU - Zhu, Ye
N1 - Publisher Copyright:
© 2022 The Authors
PY - 2022/11
Y1 - 2022/11
N2 - Elevated concentration of lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease, including coronary artery disease, stroke, peripheral artery disease, and so on. Emerging data suggest that Lp(a) contributes to the increased risk for cardiovascular events even in the setting of effective reduction of plasma low-density lipoprotein cholesterol. Nevertheless, puzzling issues exist covering potential genetic factors, Lp(a) assay, possible individuals for analysis, a cutoff point of increased risk, and clinical interventions. In the Chinese population, Lp(a) exhibited a distinctive prevalence and regulated various cardiovascular diseases in specific ways. Hence, it is valuable to clarify the role of Lp(a) in cardiovascular diseases and explore prevention and control measures for the increase in Lp(a) prevalence in the Chinese population. This Beijing Heart Society experts' scientific statement will present the detailed knowledge concerning Lp(a)-related studies combined with Chinese population observations to provide the key points of reference.
AB - Elevated concentration of lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease, including coronary artery disease, stroke, peripheral artery disease, and so on. Emerging data suggest that Lp(a) contributes to the increased risk for cardiovascular events even in the setting of effective reduction of plasma low-density lipoprotein cholesterol. Nevertheless, puzzling issues exist covering potential genetic factors, Lp(a) assay, possible individuals for analysis, a cutoff point of increased risk, and clinical interventions. In the Chinese population, Lp(a) exhibited a distinctive prevalence and regulated various cardiovascular diseases in specific ways. Hence, it is valuable to clarify the role of Lp(a) in cardiovascular diseases and explore prevention and control measures for the increase in Lp(a) prevalence in the Chinese population. This Beijing Heart Society experts' scientific statement will present the detailed knowledge concerning Lp(a)-related studies combined with Chinese population observations to provide the key points of reference.
KW - atherosclerotic cardiovascular disease
KW - calcific aortic value stenosis
KW - lipoprotein(a)
KW - scientific statement
UR - https://www.scopus.com/pages/publications/85143267263
U2 - 10.1016/j.jacasi.2022.08.015
DO - 10.1016/j.jacasi.2022.08.015
M3 - 文献综述
AN - SCOPUS:85143267263
SN - 2772-3747
VL - 2
SP - 653
EP - 665
JO - JACC: Asia
JF - JACC: Asia
IS - 6
ER -
可持续发展目标 3 良好健康与福祉